Today, we announced our third quarter earnings results. Read more about our recent highlights and outlook in our business update: https://bit.ly/3UElR2b #CRSP #CRISPRTX
CRISPR Therapeutics
Biotechnology Research
Boston, MA 97,123 followers
About us
CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom.
- Website
-
http://www.crisprtx.com
External link for CRISPR Therapeutics
- Industry
- Biotechnology Research
- Company size
- 201-500 employees
- Headquarters
- Boston, MA
- Type
- Public Company
- Founded
- 2013
- Specialties
- Gene Editing, AAV, Hematology, and Immuno-Oncology
Locations
-
Primary
Get directions
105 West First Street
Boston, MA 02127, US
-
Get directions
Baarerstrasse 14-16
Zug, CH CH-6300, CH
-
Get directions
90 Fetter Lane
London, England EC4A 1JP, GB
-
Get directions
455 Mission Bay Blvd S
San Francisco, California 94158, US
Employees at CRISPR Therapeutics
Updates
-
We are honored to share that we've been nominated for the Patient Impact Award at the 12th Annual NEVY Awards! Thank you to the New England Venture Capital Association (NEVCA) for recognizing us. Please read the #NEVCA blog post for more details: https://bit.ly/4hBx1yr
-
-
We’re proud to share that we’ve been named on the TIME Best Inventions of 2024 list! This list recognizes a wide variety of new products, software or services that are making a difference in the world. #TIMEBestInventions
-
-
#WorldHeartDay aims to raise awareness for #cardiovasculardiseases, a variety of complications affecting the heart and blood vessels. These complications result in more than 20.5 million deaths each year. Learn more about cardiovascular diseases here: https://bit.ly/3YRStbN
-
-
Did you know that familial hypercholesterolemia, or #FH, is one of the most common genetic causes of high cholesterol? In recognition of #FHAwarenessDay, learn more about this condition at the Family Heart Foundation's website: https://bit.ly/3WvAFjE
-
-
Leaders across the healthcare ecosystem will join forces at the annual World Medical Innovation Forum in Boston to discuss the industry’s latest trends, developments, and outlook. Our CEO and Chairman Dr. Samarth Kulkarni and our CFO Dr. Raju Prasad will be speaking on panels on Monday, September 23rd about the broad potential for genetic medicines. Learn more about #WMIF2024 here: https://lnkd.in/evjGVi-p
-
-
A 39-year-old man from Atlanta has become the world’s first person with sickle cell disease (SCD) to reach the summit of Kilimanjaro. He climbed Kilimanjaro with the Timmerman Traverse group that’s raising awareness for #SCD. #SickleCellAwarenessMonth
-
-
We are proud to share that Fierce Life Sciences and Fierce Healthcare named CRISPR Therapeutics as a 2024 Fierce 50 honoree in the Breakthroughs category! The annual #Fierce50 report highlights companies driving advancements in medicine, fostering innovation and shaping the future of biopharma and healthcare. Learn more here: https://bit.ly/47i9M7M #CRISPRTX
-
-
In September, we recognize #SickleCellAwarenessMonth. This is a time to raise awareness for sickle cell disease (#SCD), an inherited blood disorder that causes anemia, chronic pain, fatigue, and more. Learn more about SCD here: https://bit.ly/46rdlbm
-
Similar pages
Browse jobs
Stock
CRSP
NASDAQ
20 minutes delay
$48.27
-2.32 (-4.586%)
- Open
- 49.1
- Low
- 47.65
- High
- 49.52
Data from Refinitiv
See more info on